FDA approves new type of therapy to treat advanced urothelial cancer
FDA granted accelerated approval to Padcev, indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer
Related Articles
European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer
In prostate cancer (PCa), questions remain on indications for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging and…
European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer
In prostate cancer (PCa), questions remain on indications for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging and…
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
Pembrolizumab plus lenvatinib has shown antitumor activity and acceptable safety in patients with platinum-refractory urothelial carcinoma (UC).To eva…
Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer
This genetic association study examines the association between variants of established prostate cancer risk genes and the risk of aggressive prostate cancer.
Active surveillance should be considered for select men with Grade Group 2 prostate cancer – BMC Urology
Background Treatment decisions for localized prostate cancer must balance patient preferences, oncologic risk, and preservation of sexual, urinary and bowel function. While Active Surveillance (AS)…
Male infertility may be the world’s ‘canary down a coal mine’
A global team of experts including from the University of Melbourne has made ten recommendations to urgently tackle the worldwide decline in male fertility.
Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer
Field cancerization is characterized by areas of normal tissue affected by mutated clones. Bladder field cancerization may explain the development and…
DENGVAXIA
DENGVAXIA For the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. DENGVAXIA is approved for use in individuals 9…
Second Annual FDA ASCO WORKSHOP
Optimizing Dosage Selection Strategies in Combination Cancer Therapies.
Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data
Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to…